These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19197525)

  • 1. [Clinical and economic issues in adjuvant chemotherapy for HER-2 positive breast cancer].
    Martins SJ; Yamamoto CA
    Rev Assoc Med Bras (1992); 2008; 54(6):494-9. PubMed ID: 19197525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J; Perez EA; Pienkowski T; Bell R
    Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
    Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
    Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer.
    Costa RB; Kurra G; Greenberg L; Geyer CE
    Ann Oncol; 2010 Nov; 21(11):2153-2160. PubMed ID: 20351072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
    Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
    Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium.
    Neyt M; Huybrechts M; Hulstaert F; Vrijens F; Ramaekers D
    Health Policy; 2008 Aug; 87(2):146-59. PubMed ID: 18164510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
    Liberato NL; Marchetti M; Barosi G
    J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
    Kurian AW; Thompson RN; Gaw AF; Arai S; Ortiz R; Garber AM
    J Clin Oncol; 2007 Feb; 25(6):634-41. PubMed ID: 17308268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer.
    Metcalfe S; Evans J; Priest G
    N Z Med J; 2007 Jun; 120(1256):U2593. PubMed ID: 17589560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
    Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
    Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [HER-2/neu positive breast cancer: how to prescribe adjuvant trastuzumab (Herceptin)?].
    Belkacémi Y; Gligorov J; Mauriac L; Azria D
    Bull Cancer; 2006 Oct; 93(10):991-9. PubMed ID: 17074658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial.
    Dedes KJ; Szucs TD; Imesch P; Fedier A; Fehr MK; Fink D
    Ann Oncol; 2007 Sep; 18(9):1493-9. PubMed ID: 17761705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial.
    Purmonen TT; Pänkäläinen E; Turunen JH; Asseburg C; Martikainen JA
    Acta Oncol; 2011 Apr; 50(3):344-52. PubMed ID: 21299447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant trastuzumab therapy for HER2-positive breast cancer.
    Jahanzeb M
    Clin Breast Cancer; 2008 Aug; 8(4):324-33. PubMed ID: 18757259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer.
    Chen W; Jiang Z; Shao Z; Sun Q; Shen K
    Value Health; 2009; 12 Suppl 3():S82-4. PubMed ID: 20586989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
    Ward S; Pilgrim H; Hind D
    Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating biological agents into systemic therapy of breast cancer: trastuzumab, lapatinib, bevacizumab.
    Eniu A
    J BUON; 2007 Sep; 12 Suppl 1():S119-26. PubMed ID: 17935269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
    Gianni L; Dafni U; Gelber RD; Azambuja E; Muehlbauer S; Goldhirsch A; Untch M; Smith I; Baselga J; Jackisch C; Cameron D; Mano M; Pedrini JL; Veronesi A; Mendiola C; Pluzanska A; Semiglazov V; Vrdoljak E; Eckart MJ; Shen Z; Skiadopoulos G; Procter M; Pritchard KI; Piccart-Gebhart MJ; Bell R;
    Lancet Oncol; 2011 Mar; 12(3):236-44. PubMed ID: 21354370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moving forward: Herceptin in the adjuvant setting.
    Tan-Chiu E; Piccart M
    Oncology; 2002; 63 Suppl 1():57-63. PubMed ID: 12422056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.
    Millar JA; Millward MJ
    Pharmacoeconomics; 2007; 25(5):429-42. PubMed ID: 17488140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.